Table 1.
Baseline Demographic and Clinical Characteristics of Patients Enrolled in This Study
| Characteristic | Group | χ2 | t | P | ||
|---|---|---|---|---|---|---|
| TACE Plus Sorafenib (n=42) | TACE Alone (n=43) | |||||
| Sex (n/%) | Male | 32 (76.19%) | 31 (72.09%) | 0.186 | – | 0.666 |
| Female | 10 (23.81%) | 12 (27.91%) | ||||
| Age (median ±SD) | Years | 58.31±7.83 | 58.53±8.11 | – | −0.125 | 0.901 |
| ECOG-PS(n/%) | 0 | 9 (21.43%) | 10 (23.26%) | 0.201 | - | 0.905 |
| 1 | 29 (69.05%) | 30 (69.77%) | ||||
| 2 | 4 (9.52%) | 3 (6.97%) | ||||
| Child-Pugh(n/%) | A | 29 (69.05%) | 29 (67.44%) | 0.488 | - | 0.783 |
| B | 11 (26.19%) | 13 (30.23%) | ||||
| C | 2 (4.76%) | 1 (2.33%) | ||||
| BCLC(n/%) | B | 23 (54.76%) | 25 (58.14%) | 0.099 | - | 0.754 |
| C | 19 (45.24%) | 18 (41.86%) | ||||
| Cirrhosis(n/%) | With | 39 (92.86%) | 38 (88.37%) | 0.501 | - | 0.479 |
| Without | 3 (7.14%) | 5 (11.63%) | ||||
| Viral hepatitis(n/%) | HBV | 39 (92.86%) | 41 (95.34%) | 0.372 | - | 0.830 |
| HCV | 1 (2.38%) | 1 (2.33%) | ||||
| None | 2 (4.76%) | 1 (2.33%) | ||||
| AFP(n/%) | AFP<400 ng/dl | 13 (30.95%) | 15 (34.88%) | 0.149 | - | 0.700 |
| AFP>400 ng/dl | 29 (69.05%) | 28 (65.12%) | ||||
Note: Results reported as N (%) unless otherwise indicated.
Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; HBV, hepatitis B virus; HCV, hepatitis C virus; SD, standard deviation.